Bone Biologics Corp Warrants
BBLGW
5 hedge funds and large institutions have $8.27K invested in Bone Biologics Corp Warrants in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
166% more capital invested
Capital invested by funds: $3.11K → $8.27K (+$5.17K)
67% more funds holding
Funds holding: 3 → 5 (+2)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.18K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$11 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$110 |
BBLGW Hedge Fund Activity: Q1 2023 in Review
5 of the 6,285 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q1 2023, worth a combined $8.27K — up 166% from $3.11K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BBLGW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.18K. The largest seller was Warberg Asset Management, cutting an estimated $110.
- 5 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q1 2023, up from 3 in Q4 2022.
- Funds reported $8.27K of Bone Biologics Corp Warrants stock for Q1 2023, up 166% quarter-over-quarter.
- 2 funds opened new Bone Biologics Corp Warrants positions in Q1 2023 and 0 closed out, a net change of +2 holders.
- The largest Bone Biologics Corp Warrants buyer in Q1 2023 was Susquehanna International Group, an estimated $1.18K added.
- The largest Bone Biologics Corp Warrants seller in Q1 2023 was Warberg Asset Management, an estimated $110 sold.
Based on aggregated 13F filings for Q1 2023.